Bcr-Abl^(T315I)突变慢性髓系白血病靶向治疗的研究进展  

Research progress of targeted therapy for chronic myeloid leukemia with Bcr-Abl^(T315I) mutation

作　　者：郑燕[1] 李佳莹[1] 杨勇[2] 陈真[1] 

机构地区：[1]中国药科大学药学医学基础实验教学中心,江苏南京211198 [2]中国药科大学药物科学研究院,江苏南京211198

出　　处：《药学研究》2017年第2期96-98,共3页Journal of Pharmaceutical Research

摘　　要：慢性髓细胞白血病(chronic myeloid leukemia,CML)是一种自我更新的造血干细胞恶性增殖肿瘤。第一代酪氨酸激酶抑制剂伊马替尼的问世,为慢性髓细胞白血病患者带来了福音,但随之后来的耐药是一个巨大的挑战,尤其是Bcr-Abl^(T315I)突变引发的耐药程度最高。目前已有多种针对T315I突变的靶向治疗药物的研究,包括已上市的Ponatinib等,本文就近年来针对T315I突变的靶向治疗药物做一综述。Chronic myeloid leukemia （CML） is a self-renewing hematopoietic stem cell malignancy.The advent of the first-generation tyrosine kinase inhibitor-Imatinib has brought the gospel to the CML patients.However,resistance to Ima- tinib remains a major challenge, especially the Bcr-Abl^T3151 mutations that with the highest resistance.Fortunately, there are many of therapies targeting T3151 mutations having been reported, including the currently marketed Ponatinib.This review focused on the research progress of targeted therapies of T3151 mutation in recent years.

关 键 词：慢性髓系白血病 Bcr-Abl^T315I突变 伊马替尼耐药 靶向治疗 

分 类 号：R973[医药卫生—药品]